CN114644633B - 杂环类jak抑制剂 - Google Patents

杂环类jak抑制剂

Info

Publication number
CN114644633B
CN114644633B CN202011495497.0A CN202011495497A CN114644633B CN 114644633 B CN114644633 B CN 114644633B CN 202011495497 A CN202011495497 A CN 202011495497A CN 114644633 B CN114644633 B CN 114644633B
Authority
CN
China
Prior art keywords
alkyl
phenyl
cycloalkyl
pharmaceutically acceptable
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011495497.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114644633A (zh
Inventor
请求不公布姓名
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202011495497.0A priority Critical patent/CN114644633B/zh
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Priority to CA3222404A priority patent/CA3222404A1/en
Priority to AU2021398704A priority patent/AU2021398704A1/en
Priority to JP2023576366A priority patent/JP2024522210A/ja
Priority to US18/568,771 priority patent/US20240246984A1/en
Priority to EP21905795.7A priority patent/EP4310088A4/en
Priority to PCT/CN2021/138842 priority patent/WO2022127869A1/zh
Publication of CN114644633A publication Critical patent/CN114644633A/zh
Application granted granted Critical
Publication of CN114644633B publication Critical patent/CN114644633B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202011495497.0A 2020-12-18 2020-12-18 杂环类jak抑制剂 Active CN114644633B (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202011495497.0A CN114644633B (zh) 2020-12-18 2020-12-18 杂环类jak抑制剂
AU2021398704A AU2021398704A1 (en) 2020-12-18 2021-12-16 Heterocyclic jak inhibitor
JP2023576366A JP2024522210A (ja) 2020-12-18 2021-12-16 複素環系ｊａｋ阻害剤
US18/568,771 US20240246984A1 (en) 2020-12-18 2021-12-16 Heterocyclic jak inhibitor
CA3222404A CA3222404A1 (en) 2020-12-18 2021-12-16 Heterocyclic jak inhibitor
EP21905795.7A EP4310088A4 (en) 2020-12-18 2021-12-16 HETEROCYCLIC JAK INHIBITOR
PCT/CN2021/138842 WO2022127869A1 (zh) 2020-12-18 2021-12-16 杂环类jak抑制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011495497.0A CN114644633B (zh) 2020-12-18 2020-12-18 杂环类jak抑制剂

Publications (2)

Publication Number Publication Date
CN114644633A CN114644633A (zh) 2022-06-21
CN114644633B true CN114644633B (zh) 2026-02-03

Family

ID=81990162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011495497.0A Active CN114644633B (zh) 2020-12-18 2020-12-18 杂环类jak抑制剂

Country Status (7)

Country Link
US (1) US20240246984A1 (https=)
EP (1) EP4310088A4 (https=)
JP (1) JP2024522210A (https=)
CN (1) CN114644633B (https=)
AU (1) AU2021398704A1 (https=)
CA (1) CA3222404A1 (https=)
WO (1) WO2022127869A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115999A1 (en) * 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN111212839A (zh) * 2017-09-15 2020-05-29 艾杜罗生物科技公司 吡唑并嘧啶酮化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528918B1 (en) * 2010-01-29 2014-09-10 Nerviano Medical Sciences S.r.l. 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators
WO2016061751A1 (en) * 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2019074962A1 (en) * 2017-10-10 2019-04-18 Syros Pharmaceuticals, Inc. PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
JP7617030B2 (ja) * 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115999A1 (en) * 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN111212839A (zh) * 2017-09-15 2020-05-29 艾杜罗生物科技公司 吡唑并嘧啶酮化合物及其用途

Also Published As

Publication number Publication date
US20240246984A1 (en) 2024-07-25
WO2022127869A1 (zh) 2022-06-23
AU2021398704A1 (en) 2024-03-21
EP4310088A1 (en) 2024-01-24
CA3222404A1 (en) 2022-06-23
JP2024522210A (ja) 2024-06-11
CN114644633A (zh) 2022-06-21
EP4310088A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
CN113631557B (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
JP6427257B2 (ja) Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン
AU2014358792B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AU2011256380B2 (en) Macrocyclic compounds as Trk kinase inhibitors
HK1223100A1 (zh) 杂环化合物
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
CN116670119B (zh) 作为btk抑制剂的桥联双环化合物
EP3768272B1 (en) Jak inhibitors
JPWO2015008839A1 (ja) Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
KR102926602B1 (ko) 티로신 키나아제 2 활성을 조정하기 위한 헤테로사이클릭 화합물
CN114644633B (zh) 杂环类jak抑制剂
CN114591351A (zh) 一种多环化合物及其制备方法和用途
RU2826012C2 (ru) Гетероциклические соединения для опосредования активности тирозинкиназы 2
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
WO2025104122A1 (en) Heterocyclic derivatives as janus kinase inhibitors
CN119968375A (zh) 作为Janus激酶抑制剂的杂环衍生物
HK40095618A (zh) 作为btk抑制剂的桥联双环化合物
CN120058741A (zh) Dgk抑制剂化合物及其应用
HK40042275A (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK40042275B (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
CN112384506A (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant